title: Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
abstract: Cholangiocarcinoma is a disease with a poor prognosis. A human cholangiocarcinoma cell line, TK, was previously established to enable further understanding of the disease. We conducted this investigation to determine whether or not the TK line is useful for pharmacokinetic study of the chemotherapeutic agent gemcitabine (GEM). Along with the BXPC3 human pancreatic adenocarcinoma cell line, the sensitivity to and effects on the TK cell line of GEM were compared. The influence of deoxycytidine kinase (dCK) transduction was also comparatively investigated. The effects of GEM in terms of drug sensitivity of the TK cell line, cell cycle and levels of transcripts of key enzymes were comparable to the BXPC3 cell line. Responses to the drug were similar in both cell lines. In contrast to pancreatic carcinoma, cell lines for research on cholangiocarcinoma have been limited. This study suggests the application of the TK cell line to the pharmacokinetic study of the chemosensitization of therapeutic drugs, such as GEM.
authors.affiliation: Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Minori
authors.initials: M
authors.lastname: Kamada
authors.affiliation: Department of Molecular Cell Biology, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Kohei
authors.initials: K
authors.lastname: Akiyoshi
authors.affiliation: Department of Molecular Immunology, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Nobutake
authors.initials: N
authors.lastname: Akiyama
authors.affiliation: Department of Surgery, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Naotake
authors.initials: N
authors.lastname: Funamizu
authors.affiliation: Institute of DNA Sciences, Yokohama, Japan.
authors.forename: Michiko
authors.initials: M
authors.lastname: Watanabe
authors.affiliation: Department of Molecular Cell Biology, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Kouki
authors.initials: K
authors.lastname: Fujioka
authors.affiliation: Department of Molecular Cell Biology, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Kei-Ichi
authors.initials: K
authors.lastname: Ikeda
authors.affiliation: Department of Molecular Cell Biology, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Manome
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001650:Bile Duct Neoplasms / Q000188:drug therapy* / Q000473:pathology; D001653:Bile Ducts, Intrahepatic / Q000187:drug effects / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine